Goodwin's PCAP has updated our 2022 Form 10-Q Form Check Table for the quarter ended September 30, 2022. We are very excited to provide this tool to public companies to use in preparing and reviewing their Form 10-Qs.

Goodwin's Public Company Advisory Practice has completed its 2022-2023 Form 10-K Form Check Document for December 31 fiscal year-end companies.

Halloween has come early this October, as the U.S. Department of Justice has raised the somewhat spooky prospect of a federal investigation into possible anticompetitive behavior among U.S. private equity firms. This development certainly is surprising for those who experience first-hand how fiercely competitive the private equity and buyout world can be for deals of all sizes.

At a field hearing on credit reporting in Detroit, Michigan, Director Richard Cordray announced that the CFPB had adopted a final rule defining "larger participants" for consumer reporting agencies. Under Section 1074 of the Dodd-Frank Act, the CFPB has authority to supervise nonbank "larger participant[s] in markets for other consumer financial products or services."

The Department of Defense Appropriations Act for Fiscal Year 2010 was signed into law by President Obama on December 19, 2009. The Act extends the eligibility for and the duration of the temporary federal COBRA subsidy provided by the American Recovery and Reinvestment Act of 2009.

U.S. Energy Secretary Stephen Chu recently announced the launch of a new federal program, America’s Next Top Energy Innovator, aimed at matching energy-related intellectual property generated by national laboratories such as the National Renewable Energy Laboratory ("NREL"), Argonne and Lawrence-Berkeley with start-up companies eager to license those technologies and drive them toward commercialization.

The FRB, OCC and FDIC approved a final rule (the "Final Rule") implementing certain provisions of Section 171 of the Dodd-Frank Act (commonly known as the Collins Amendment).

Beginning February 15, 2007, investment advisers and managers of public and private investment funds seeking relief from the rules of the Commodity Futures Trading Commission ("CFTC") must file certain notices of exclusion or exemption electronically using the online registration system maintained by the National Futures Association (the "NFA").

The Staff of the SEC’s Division of Investment Management recently issued guidance for mutual funds and their investment advisers relating to the use of tri-party repurchase agreements.

The U.S. Court of Appeals for the Eleventh Circuit recently affirmed the denial of class certification in an action against State Farm.

There are two new statutes, one which has been enacted and is scheduled to take effect in March and one which is pending before the legislature, that will change many of the ways that trusts have traditionally been administered.

This update to our December 4, 2008 REIT Alert addresses capped cash option stock dividends, one of the cash preservation strategies available to REITs.

Massachusetts recently promulgated rules, effective January 1, 2009, that may require certain investment funds and other pass-through entities that maintain an office or do business in Massachusetts to withhold on certain members’ distributive shares of Massachusetts-source income.

On April 20, 2026, Eli Lilly & Company (“Lilly”) and Kelonia Therapeutics, Inc. (“Kelonia”) announced an agreement for Lilly to acquire Kelonia in an all-cash transaction expected to close in the second half of 2026.

Teva Pharmaceutical Industries and Samsung Bioepis have announced a strategic partnership to commercialize OPUVIZ, a biosimilar referencing EYLEA, in the Canadian market. The agreement divides responsibilities between Samsung Bioepis handling product registration and manufacturing while Teva Canada leads commercialization efforts. OPUVIZ has already received Health Canada approval for treating multiple eye conditions including wet age-related macular degeneration and diabetic macular edema.

On November 11, 2022, STADA Arzneimittel AG ("STADA") and Xbrane Biopharma AB ("Xbrane") announced that the European Commission has granted a marketing authorization for XIMLUCI (ranibizumab), a biosimilar to Genentech's LUCENTIS.

Numerous public companies have declared themselves a "remote-only" or "remote-first" company. Recently, we learned that the SEC Staff will not declare a registration statement effective...

On October 31, 2024, the CFPB announced that it had entered into a consent order with a credit union, resolving allegations that the union had ineffectively rolled out a new online banking platform that left consumers without adequate access to basic banking functions, and thereby inflicted financial harm.

On October 23, 2023, Celltrion announced FDA approval for ZYMFENTRA, a subcutaneous formulation for maintenance therapy for patients with moderately to severely active ulcerative colitis ...

Chime Biologics and Daewoong Pharmaceutical have formed a strategic partnership to develop and manufacture a dupilumab biosimilar candidate targeting Sanofi and Regeneron's blockbuster DUPIXENT.